OBJECTIVE:To investigate the status quo and tendency of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015. METHODS:The prescriptions of breast cancer patients in 11 hospitals of Zhe-jiang province were analyzed retrospectively in respects of consumption sum,DDDs,DDC,etc. RESULTS:The consumption sum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 increased from 2530192.33 yuan to 6201691.54 yuan,and its proportion in total consumption sum increased from 13.93％ to 17.40％,showing in-creasing tendency. The anastrozole always took up the first place in the list of consumption sum. Tamoxifen,anastrozole and letro-zole took up the top 3 places in the list of DDDs. Goserelin took up the first place in the list of DDC. CONCLUSIONS:The pre-scription amount and consumptionsum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 show year-on-year growth trend;and those drugs which are safe,effective,economical and convenient predomi-nate in clinic.%目的:了解浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的临床应用情况.方法:回顾性分析浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的使用数据,包括销售金额、用药频度(DDDs)、日均费用(DDC)等.结果:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的销售金额由2530192.33元增长至6201691.54元,在药品总销售金额中的占比由13.93％上升至17.40％,均呈上升趋势.阿那曲唑的销售金额各年度均排名首位.他莫西芬、阿那曲唑和来曲唑的DDDs各年度均排名前3位.DDC各年度排名首位的是戈舍瑞林.结论:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物处方量及销售金额都呈逐年增长趋势;安全有效、经济方便的药物在临床使用中占优势.
展开▼
